Novavax (NVAX) stock jumps as the company beats with its Q4 2025 revenue and records full-year profitability. Read more here.
MRP's portfolio yield is rising, driven by non-Lennar deals at 11%, with run-rate FFO now at $0.77 and potential for further ...
Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results